1. Home
  2. FDMM vs CCCC Comparison

FDMM vs CCCC Comparison

Compare FDMM & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FDMM

Freedom Metals Acquisition Corp. Class A Ordinary Shares

N/A

Current Price

$9.80

Market Cap

368.5M

Sector

Finance

ML Signal

N/A

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$3.66

Market Cap

404.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FDMM
CCCC
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
368.5M
404.7M
IPO Year
2026
2020

Fundamental Metrics

Financial Performance
Metric
FDMM
CCCC
Price
$9.80
$3.66
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$12.20
AVG Volume (30 Days)
N/A
2.6M
Earning Date
N/A
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
16.45
EPS
N/A
N/A
Revenue
N/A
$35,947,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.02
52 Week Low
N/A
$1.69
52 Week High
N/A
$5.17

Technical Indicators

Market Signals
Indicator
FDMM
CCCC
Relative Strength Index (RSI) N/A 47.61
Support Level N/A $3.40
Resistance Level N/A $3.91
Average True Range (ATR) 0.00 0.19
MACD 0.00 0.02
Stochastic Oscillator 0.00 50.00

Price Performance

Historical Comparison
FDMM
CCCC

About FDMM Freedom Metals Acquisition Corp. Class A Ordinary Shares

Freedom Metals Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Share on Social Networks: